How should phase III therapeutic trials in multiple sclerosis be evaluated: advances and challenges

Authors
Waubant, E Goodkin, D
Citation
E. Waubant et D. Goodkin, How should phase III therapeutic trials in multiple sclerosis be evaluated: advances and challenges, REV NEUROL, 155, 1999, pp. S7-S12
Citations number
19
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
REVUE NEUROLOGIQUE
ISSN journal
00353787 → ACNP
Volume
155
Year of publication
1999
Supplement
2
Pages
S7 - S12
Database
ISI
SICI code
0035-3787(199903)155:<S7:HSPITT>2.0.ZU;2-K